Drug Details

General Information of the Drug (ID: DR6887)
Name
Cefepime
Synonyms
cefepime; Maxipime; Cefepima; Cefepimum [Latin]; Cefepima [Spanish]; Cefepimum; 88040-23-7; Axepim; BMY-28142; E-Cefepime; CFPM; UNII-807PW4VQE3; 807PW4VQE3; CHEBI:478164; BMY 28142; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; Cefepime (USAN/INN); Cefepime [USAN:INN:BAN]; J01DE01; Cefepime(Maxipime)/; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); Cefepime, Antibiotic for Culture Media Use Only; CHEMBL186; SCHEMBL65720; VNRX-5022; DTXSID70873208; BCPP000292; HMS2089M18; ABP000468; BDBM50350470; AKOS015850865; AKOS016014147; BCP9000504; DB01413; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate; C08111; D02376; AB01275446-01; A842445; Q27294816; (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-methoxyimino-1-oxoethyl]amino]-3-[(1-methyl-1-pyrrolidin-1-iumyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-azanyl-1,3-thiazol-4-yl)-2-methoxyimino-ethanoyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-methylpyrrolidin-1-ium
    Click to Show/Hide
Molecular Type
Small molecule
Disease Bacterial infection [ICD-11: 1A00-1C4Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Bioavailability
The bioavailability of drug is 82.3%
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.2 mL/min/kg
Elimination
85% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 2.0 +/- 0.3 hours (in normal patients)
Metabolism
The drug is metabolized via the hepatic
Unbound Fraction
The unbound fraction of drug in plasma is 0.78%
Vd
The volume of distribution (Vd) of drug is 18.0 +/- 2.0 L
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C19H24N6O5S2
PubChem CID
5479537
Canonical SMILES
C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-]
InChI
1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1
InChIKey
HVFLCNVBZFFHBT-ZKDACBOMSA-N
CAS Number
CAS 88040-23-7
ChEBI ID
CHEBI:478164
TTD Drug ID
D0A1CB
DrugBank ID
DB01413
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Tea Polyphenols      Theaceae     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Klebsiella pneumoniae Microorganism model Klebsiella pneumoniae
                    Experimental
                    Result(s)		 Tea polyphenols used in combination with commonly used antibiotics showed synergistic bactericidal effect against multidrug-resistant Klebsiella pneumoniae.
Target and Pathway
Target(s) Bacterial Penicillin binding protein 2 (Bact mrdA)  Molecule Info  [3]
References
Reference 1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Reference 2 In-vitro antibacterial effect of tea polyphenols combined with common antibiotics on multidrug-resistant Klebsiella pneumoniae. Minerva Med. 2020 Dec;111(6):536-543.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link